A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

Until Insulet's Omnipod came on the market at the end of 2005, all insulin pumps consisted of a controller and insulin reservoir attached to the injection site by a long flexible tube. The Omnipod ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

Sellers may have panicked about the company's future prospects. Morningstar analyst Debbie Wang, in a February 26 note, said Insulet's Omnipod system "is inconspicuous and easy to use and has so far ...

Blush Novelties Amazon Length: 9.5 inches Material: Silicone and acrylic Type: Hand-powered With its basic shape and no-nonsense design, this vacuum pump is ideal for beginners who are pump-curious.

Manama, Feb. 22 (BNA): Shaikh Ali bin Khalifa Al Khalifa, Secretary General of the Royal Humanitarian Foundation (RHF), received a donation from Vitol to support the provision of five insulin pumps ...

Massachusetts-based company's total revenue jumped 17.2per cent to $597.5 million for the quarter ended December 31, beating analysts' estimates of $582.8 million. Sales of Omnipod insulin pumps ...

Food that can support insulin sensitivity include non-starchy ... to reduce their risk of developing type 2 diabetes by losing 5% to 7% of their body weight. A person can consult a doctor to ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed ... The automated insulin delivery technology maker reported sales of $597.5 ...

The automated insulin delivery ... U.S. Omnipod revenue increased 12.4% to $443.7 million, and International Omnipod revenue rose to $142.0 million, an increase of 33.5%, or 33.1%, in constant ...

He emphasized the strong demand and adoption of Omnipod 5 across both type 1 ... with the company aiming to reach over 40% of the 2.5 million insulin-intensive type 2 population in 2025.